Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Viewpoint
  • Published:

Significance of BRAF mutations in papillary thyroid carcinoma: prognostic and therapeutic implications

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kimura ET et al. (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63: 1454–1457

    CAS  PubMed  Google Scholar 

  2. Xing M (2005) BRAF mutation in thyroid cancer. Endocr Relat Cancer 12: 245–262

    Article  CAS  Google Scholar 

  3. Ciampi R et al. (2005) Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 115: 94–101

    Article  CAS  Google Scholar 

  4. Knauf JA et al. (2005) Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65: 4238–4245

    Article  CAS  Google Scholar 

  5. Giordano TJ et al. (2005) Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24: 6646–6656

    Article  CAS  Google Scholar 

  6. Castro P et al. (2006) PAX8-PPARγ rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91: 213–220

    Article  CAS  Google Scholar 

  7. Xing M et al. (2005) BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90: 6373–6379

    Article  CAS  Google Scholar 

  8. Vasko V et al. (2005) High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab 90: 5265–5269

    Article  CAS  Google Scholar 

  9. Nikiforova MN et al. (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88: 5399–5404

    Article  CAS  Google Scholar 

  10. Ouyang B et al. Inhibitors of raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res, in press

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to James A Fagin.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Groussin, L., Fagin, J. Significance of BRAF mutations in papillary thyroid carcinoma: prognostic and therapeutic implications. Nat Rev Endocrinol 2, 180–181 (2006). https://doi.org/10.1038/ncpendmet0161

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0161

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing